Lilly (Eli) (LLY) stock
Health Care · Pharmaceuticals
Lilly (Eli) (LLY) is a Pharmaceuticals company in the Health Care sector, headquartered in Indianapolis, Indiana. As of October 23, 2026, LLY closed at $1,273.46, a market capitalization of $1.14 trillion, the 11th largest company in the S&P 500. Over the last twelve months it generated $79.67 billion in revenue (+48% year over year) and $13.56 billion in free cash flow. The stock trades at 42.7x trailing earnings and 27.0x forward earnings.
- 1-year total return: +56.1% (dividends reinvested)
- 5-year return: +40.5% a year
- 52-week range: $809.63 – $1,321.21
- Gross margin 83.4%, operating margin 54.2%
- Dividend yield: 0.54%, 11 straight years of increases
- FI Handbook report card: B across 10 metrics
- Largest of 60 Health Care stocks in the S&P 500
LLY price chart
1Y price change: +55.1% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| LLY | +10.6% | +19.1% | +56.1% | +31.1% | +40.5% | +34.3% | +14.3% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1972.
LLY key statistics
- Market cap
- $1.1T
- #11 in S&P 500
- P/E (TTM)
- 42.7x
- Forward P/E
- 27.0x
- EPS (TTM)
- $29.79
- Revenue (TTM)
- $79.7B
- +48%
- Free cash flow
- $13.6B
- Gross margin
- 83.4%
- Operating margin
- 54.2%
- Return on equity
- 102.3%
- Dividend yield
- 0.54%
- 52-week range
- $809.63 – $1,321
- Beta
- 0.45
- Price / sales
- 14.3x
- EV / EBITDA
- 28.3x
- Debt / equity
- 1.62x
- Employees
- 50,000
LLY report card
BTen fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth47.7%A
- Gross margin83.4%A
- Operating margin54.2%A
- FCF margin17.0%B
- Return on equity102.3%A
- Net debt / EBITDA1.1xC
- Forward P/E27.0xC
- PEG ratio1.2xB
- Shareholder yield0.9%D
- Share count change / yr-0.3%C
Eli Lilly and financials
Revenue went from $21.2B in fiscal 2016 to $65.2B in fiscal 2025, growing 13.3% a year.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.2B | $20.0B | $21.5B | $22.3B | $24.5B | $28.3B | $28.5B | $34.1B | $45.0B | $65.2B |
| Gross profit | $15.5B | $15.5B | $16.8B | $17.6B | $19.1B | $21.0B | $21.9B | $27.0B | $36.6B | $54.1B |
| Net income | $2.7B | -$204.1M | $3.2B | $8.3B | $6.2B | $5.6B | $6.2B | $5.2B | $10.6B | $20.6B |
| EPS (diluted) | $2.58 | $-0.19 | $3.13 | $8.89 | $6.79 | $6.12 | $6.90 | $5.80 | $11.71 | $22.95 |
| Buybacks | $600.1M | $299.8M | $4.2B | $4.4B | $500.0M | $1.3B | $1.5B | $750.0M | $2.5B | $4.1B |
| Dividends paid | $2.2B | $2.2B | $2.3B | $2.4B | $2.7B | $3.1B | $3.5B | $4.1B | $4.7B | $5.4B |
| Diluted shares | 1.1B | 1.1B | 1.0B | 935.7M | 912.5M | 911.7M | 904.6M | 903.3M | 904.1M | 899.3M |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into LLY?
A reverse DCF asks what growth the current price requires. With an enterprise value of $1.2T and $13.6B of trailing free cash flow, Eli Lilly and needs to grow free cash flow about 50.2% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return.
P/E ratio history
Current 55.5x vs. median 33.2x (10th–90th percentile 9.0x–84.8x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
LLY dividend
- Dividend yield
- 0.54%
- Annual dividend
- $6.92
- Years of increases
- 11
- 5-yr dividend growth
- 15.2%
- per year
- Payout ratio
- 22%
- Payments per year
- 4
Regular dividends per share by calendar year; special dividends excluded. Current year omitted until complete.
LLY earnings
Next report: October 29, 2026. Eli Lilly and has beaten EPS estimates 5 quarters in a row. Last quarter's revenue was $23.0B (+48% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Aug 5, 2026 | $6.58 | $8.38 | +27.3% |
| Apr 30, 2026 | $6.79 | $8.55 | +25.9% |
| Feb 4, 2026 | $6.91 | $7.54 | +9.1% |
| Oct 30, 2025 | $5.89 | $7.02 | +19.1% |
| Aug 7, 2025 | $5.59 | $6.31 | +12.9% |
| May 1, 2025 | $3.46 | $3.34 | -3.4% |
| Feb 6, 2025 | $5.07 | $5.32 | +5.0% |
| Oct 30, 2024 | $1.47 | $1.18 | -19.5% |
Stocks like LLY
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 JNJ Johnson & Johnson | -1.42% | +40% | $635.1B | 40.0x | Compare |
 MRK Merck & | -1.34% | +72% | $358.4B | 117.2x | Compare |
 PFE Pfizer | -1.28% | +30% | $171.2B | 39.5x | Compare |
 BMY Bristol-Myers Squibb | -2.41% | +47% | $125.6B | 13.5x | Compare |
 ZTS Zoetis | -1.18% | -44% | $33.5B | 13.3x | Compare |
 VTRS Viatris | -2.60% | +81% | $20.7B | — | Compare |
 ABBV AbbVie | +0.16% | +29% | $504.8B | 80.7x | Compare |
 UNH UnitedHealth | -1.62% | +19% | $375.3B | 26.9x | Compare |
LLY news
- 3 Massive Catalysts That Could Ignite an Eli Lilly Stock Rally on Oct 29 · Oct 25, 2026
- New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer · Oct 25, 2026
- Eli Lilly's Next-Generation Ovarian Cancer Drug Shows 79% Response Rate, 100% Disease Control In New Data · Oct 24, 2026
- Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026 · Oct 24, 2026
- 2 Growth Stocks to Hold for the Next Decade (Hint: These Aren’t AI Stocks) · Oct 23, 2026
LLY stock FAQ
What is LLY's market cap?
Lilly (Eli)'s market capitalization is $1.14 trillion as of October 23, 2026, ranking 11th in the S&P 500.
What is LLY's P/E ratio?
LLY trades at a trailing price-to-earnings ratio of 42.7x and a forward P/E of 27.0x. Its median P/E over the period we track is 33.2x.
Does LLY pay a dividend?
Yes. Lilly (Eli) pays $6.92 per share a year, a 0.54% yield. It has raised its dividend 11 years in a row. Dividends grew 15.2% a year over the last five years.
How much has LLY stock returned?
Including reinvested dividends, LLY returned +56.1% over one year, +40.5% a year over five years, +34.3% a year over ten years through October 23, 2026.
Is LLY stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Lilly (Eli) must grow free cash flow about 50% a year for the next decade. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
When does LLY report earnings?
Lilly (Eli) is expected to report earnings on October 29, 2026. It has beaten EPS estimates 5 quarters in a row.
How many employees does Lilly (Eli) have?
Lilly (Eli) has about 50,000 full-time employees, or $1.6 million of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology